ストックスクリーナーアプリを入手
3.80
2.15%
0.08
アフターアワーズ：
3.80
前日終値:
$3.72
開ける：
$3.71
24時間の取引高:
3,184
Relative Volume:
0.21
時価総額：
$189.64M
収益：
-
当期純損益:
-
株価収益率:
-5.1764
EPS:
-0.7341
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.52%
1か月 パフォーマンス:
-11.83%
6か月 パフォーマンス:
-5.24%
1年 パフォーマンス:
+1.33%
1日の値動き範囲:
$3.70
$3.80
1週間の範囲:
$3.6269
$3.93
52週間の値動き範囲:
$3.31
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.80 | 189.64M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | アップグレード | Stifel | Hold → Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Underperform |
| 2020-05-13 | ダウングレード | Kepler | Buy → Reduce |
| 2020-05-12 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-05-12 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 繰り返されました | B. Riley FBR | Buy |
| 2019-06-25 | 開始されました | Stifel | Hold |
| 2019-04-24 | 開始されました | SVB Leerink | Outperform |
| 2019-04-22 | 開始されました | Barclays | Overweight |
すべてを表示
Genfit Adr (GNFT) 最新ニュース
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Open Week Sharply Higher in Monday Trading - MSN
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Genfit: New EASL-EASD-EASO guidelines include NIS2+TipRanks.com - TipRanks
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary ... - GlobeNewswire
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Is Genfit (GNFT) Stock a Solid Choice Right Now - Yahoo Movies UK
European Equities Traded in the US as American Depositary Receipts Start Week Higher - MSN
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine - Ipsen
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? - Yahoo New Zealand News
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana - Yahoo Finance
The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing - Yahoo Finance
Genfit Adr (GNFT) 財務データ
Genfit Adr (GNFT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):